The Future Of Pharma Reps: 5 Ways AI Will Transform Pharmaceutical Sales Representatives

Over the past 15 years, I have given hundreds of keynotes to pharmaceutical companies around the world. One question comes up remarkably often, especially when we talk about artificial intelligence, digital health and the changing role of physicians: what will happen to pharma reps?

It is a reasonable question. Pharmaceutical representatives still play a major role in how companies communicate with healthcare professionals, but almost every part of that relationship is changing. Physicians have less time, access is becoming harder, medical information is increasingly available on demand, and AI is starting to influence how clinicians search for and interpret evidence. Based on the discussions I have had with pharma teams around the world, this is my vision of how the role could evolve.

1. Pharma reps will increasingly become scientific liaisons

The traditional model of the pharmaceutical representative was largely built around delivering information. That model becomes less valuable when physicians can access product information, clinical evidence and treatment comparisons within seconds through large languega models (LLMs), some of those specifically built for medical purposes.

It means the level of the conversation has to rise. I expect the most valuable pharma representatives to become much more scientifically sophisticated. They will need to understand more the evidence around their products, know the surrounding therapeutic landscape, recognize the limitations of studies and be able to discuss how new findings fit into clinical practice.

In practical terms, companies may need to rethink how they train field teams. Product knowledge alone will not be enough. Reps will increasingly need stronger scientific literacy, an understanding of AI-supported clinical workflows and the ability to have deeper conversations with physicians.

The future rep will have to provide something a physician cannot get from an AI in seconds.

2. Pharma will compete for inclusion in algorithms, not only for physicians’ attention

For decades, pharmaceutical companies have competed for physicians’ attention. Now physicians are increasingly using AI systems to summarize literature, support diagnosis, compare treatment options and navigate clinical guidelines. Over time, some of these systems may become an important interface between medical evidence and the physician.

This creates a new challenge for pharma. Imagine that a physician asks an AI assistant which treatment options are appropriate for a particular patient. The answer may be based on guidelines, published evidence, regulatory documents and other structured sources.

At that point, it matters whether a company’s evidence can actually be found, interpreted and represented correctly by these systems. This will make issues such as structured scientific information, data quality, transparency, interoperability and machine-readable evidence increasingly important.

In the future, pharma companies may have to think about share of answer alongside share of voice.

3. AI will prepare reps for every physician meeting

One of the clearest opportunities for AI is helping representatives prepare much better for interactions with healthcare professionals. Before a meeting, an AI system could summarize the physician’s specialty, research interests, recent publications, previous interactions with the company, relevant new evidence and likely questions.

Instead of entering a meeting with largely standardized material, the representative could arrive with a much better understanding of what might actually be useful for that particular physician.

AI could also support the work after the meeting. It could help structure notes, identify recurring questions, recognize patterns across hundreds of interactions and highlight issues that should be communicated back to Medical Affairs or other teams.

This is where AI augmentation can make the human interaction more valuable rather than simply more efficient. The physician gets a conversation that is more relevant to their work, while the representative spends less time collecting information and more time understanding what matters.

4. Access to physicians will continue to shrink

This trend was already underway long before generative AI appeared. Physicians are increasingly busy. Hospitals and healthcare systems may restrict commercial access. More communication happens digitally, and clinicians have more ways to obtain information without arranging a meeting.

AI will probably accelerate this. If a physician can get a useful answer immediately from a trusted AI system, there will be even less reason to spend twenty minutes in a meeting that provides generic information.

That makes each human interaction more valuable.

Companies may therefore need to think less about the number of interactions and more about their quality. A five-minute conversation that addresses a highly relevant clinical issue could become far more useful than a longer standardized presentation.

AI will raise the bar for what a field interaction must deliver.

5. AI will take over much of basic information delivery

Many questions that once required a person can increasingly be answered by digital systems. What does the latest study show? How does this treatment compare with another? What were the inclusion criteria in a particular trial? What do current guidelines recommend?

These are exactly the kinds of information tasks AI systems are becoming very good at. Pharma companies will probably develop increasingly sophisticated compliant AI systems that can provide healthcare professionals with approved scientific information whenever they need it.

This again changes the role of the representative. Their value will increasingly come from understanding context, recognizing what the physician is actually trying to solve, navigating complex situations and building trusted professional relationships.

The pharma rep is unlikely to disappear, but the job will substantially evolve

Whenever I discuss AI with pharmaceutical companies, the conversation about representatives often turns quickly toward replacement. I think the more interesting question is how the role changes when information becomes abundant, physicians become augmented by AI, and access becomes more difficult.

My expectation is that the bar will rise considerably. The successful pharma representative of the future will be more scientific, more technologically supported, better prepared and more useful to the physician.

That is a much more demanding role and potentially a much more valuable one.